Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.

[1]  G. Clark,et al.  In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors? , 1988, Science.

[2]  M. Press,et al.  Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. , 1988, Endocrinology.

[3]  R. Weinberg,et al.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.

[4]  I. Verma,et al.  Expression of cellular oncogenes in human malignancies. , 1984, Science.

[5]  B. Gusterson,et al.  c-erbB-2 expression in benign and malignant breast disease. , 1988, British Journal of Cancer.

[6]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[7]  G. Clark,et al.  Amplification of c-erbB-2 and aggressive human breast tumors? , 1988, Science.

[8]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[9]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[10]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[11]  J. Yokota,et al.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. , 1987, Cancer research.

[12]  T. Boone,et al.  Identification and characterization of the protein encoded by the human N-myc oncogene. , 1986, Science.

[13]  M. J. van de Vijver,et al.  Amplification and over-expression of the neu oncogene in human breast carcinomas. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[16]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[17]  J. Bishop.  Cellular oncogenes and retroviruses. , 1983, Annual review of biochemistry.

[18]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[19]  J. Bacus,et al.  The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. , 1988, American journal of clinical pathology.

[20]  H. Battifora,et al.  The influence of protease digestion and duration of fixation on the immunostaining of keratins. A comparison of formalin and ethanol fixation. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[22]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[23]  D. Slamon,et al.  Expression of p21 ras oncoproteins in human cancers. , 1986, Cancer research.

[24]  K. M. Kelly,et al.  Estrogen and Progestin Binding in Cytosols of Ovarian Adenocarcinomas , 1979, Obstetrics and gynecology.

[25]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[26]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[27]  M. Press,et al.  An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[28]  M. Press,et al.  Immunocytochemical identification of estrogen receptor in ovarian carcinomas. Localization with monoclonal estrophilin antibodies compared with biochemical assays. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[29]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[30]  R. Larson,et al.  Studies of the human c-myb gene and its product in human acute leukemias. , 1986, Science.

[31]  D. Slamon.  Proto-oncogenes and human cancers. , 1987, The New England journal of medicine.

[32]  M. Cline,et al.  Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. , 1989, Oncogene.

[33]  H. Varmus.  The molecular genetics of cellular oncogenes. , 1984, Annual review of genetics.